AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Invesco Ltd.

Invesco Ltd. reduced its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 54.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,288 shares of the biotechnology company's stock after selling 28,002 shares during the period. Invesco Ltd. owned 0.08% of AnaptysBio worth $308,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. JPMorgan Chase & Co. lifted its holdings in AnaptysBio by 191.4% in the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company's stock valued at $1,130,000 after acquiring an additional 22,164 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of AnaptysBio by 41.0% in the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock valued at $4,428,000 after purchasing an additional 97,200 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after purchasing an additional 143,584 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of AnaptysBio during the 4th quarter worth about $311,000. Finally, AlphaQuest LLC raised its holdings in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after buying an additional 4,237 shares during the period.

Analyst Ratings Changes

A number of brokerages have weighed in on ANAB. Guggenheim reiterated a "buy" rating on shares of AnaptysBio in a research report on Monday, March 3rd. HC Wainwright reiterated a "neutral" rating and issued a $22.00 target price on shares of AnaptysBio in a report on Tuesday, March 4th. Wells Fargo & Company upped their price target on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. lifted their price objective on AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, Wolfe Research initiated coverage on AnaptysBio in a research note on Tuesday, February 4th. They set an "outperform" rating and a $25.00 target price on the stock. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, AnaptysBio currently has an average rating of "Moderate Buy" and an average price target of $33.63.

AnaptysBio Stock Performance

AnaptysBio stock opened at $21.19 on Monday. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $41.31. The company has a market capitalization of $626.67 million, a price-to-earnings ratio of -3.49 and a beta of -0.20. The stock has a fifty day moving average of $18.24 and a two-hundred day moving average of $19.01.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.89. The company had revenue of $43.11 million for the quarter, compared to analysts' expectations of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has initiated a share repurchase plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.